Chlamydia and Gonorrhea: Silent Infections, Real Risks

Chlamydia and gonorrhea often cause no symptoms, especially in the cervix, throat, or rectum. When symptoms occur, they may include discharge, burning urination, pelvic pain, testicular pain, or bleeding after sex.

Untreated infection can lead to pelvic inflammatory disease, epididymitis, chronic pain, pregnancy complications, and infertility. Testing is simple and may use urine or swabs from exposed sites.

Antibiotic treatment is effective when taken correctly. Recent partners usually need testing and treatment to prevent reinfection. Avoid sexual contact until treatment is complete and the recommended waiting period has passed.

Regular screening is a health habit, not a sign of mistrust. It supports honest relationships and prevents long-term harm from silent infection.

Silent but consequential

Chlamydia and gonorrhea are among the most common bacterial STIs, and both are frequently symptomless—especially in women—which allows them to spread unknowingly. When symptoms do occur, they may include unusual discharge, burning during urination, or pelvic pain. Untreated, they can cause pelvic inflammatory disease and threaten fertility.

Testing and treatment

Both are diagnosed with simple urine tests or swabs and are usually cured with antibiotics. Partners need treatment too, and it is important to avoid sex until treatment is complete to prevent reinfection and ping-ponging between partners. Because reinfection is common, a repeat test a few months later is often recommended.

Why They Are Called 'Silent' Infections

The term 'silent infection' is not hyperbole. Studies consistently find that 70–90% of people with chlamydia and up to 50% of people with gonorrhea experience no symptoms whatsoever. In people with cervixes, asymptomatic rates are particularly high — a young person can carry and transmit chlamydia for months or even years without any sign that anything is wrong. By the time symptoms do appear, the infection may have already ascended to the reproductive organs and begun causing damage.

This silence is why screening — rather than symptom-driven testing — is the cornerstone of controlling these infections. Waiting for pain, discharge, or other signals means the infection has likely already done its worst. Regular testing according to recommended schedules detects infections while they are still confined to the initial infection site and easily treatable with a single course of antibiotics.

Transmission and Risk Factors

Both chlamydia (caused by Chlamydia trachomatis) and gonorrhea (caused by Neisseria gonorrhoeae) are transmitted through unprotected vaginal, anal, and oral sex. They infect the urethral and genital mucosa in people of all sexes, as well as the rectum, throat, and eyes if exposed. Newborns can acquire gonorrheal or chlamydial conjunctivitis during delivery through an infected birth canal — a preventable complication addressed by antibiotic eye drops routinely administered at birth in many countries.

Risk factors that increase the likelihood of acquisition include: being under 25 and sexually active (younger people have higher biological susceptibility and often higher rates of partner change); having multiple concurrent or sequential partners; inconsistent condom use; having a previous STI diagnosis (which indicates behavioral and network factors associated with ongoing risk); and living in communities with higher background prevalence, because even with similar behaviors, exposure probability increases when infections are more common.

Potential Complications of Untreated Infection

In people with reproductive tracts, untreated chlamydia and gonorrhea are leading causes of pelvic inflammatory disease (PID) — an infection of the uterus, fallopian tubes, and surrounding structures. PID causes pelvic pain, fever, and, when recurrent or treated late, permanent scarring that can lead to infertility, ectopic pregnancy, and chronic pelvic pain. Estimates suggest that one episode of PID results in tubal factor infertility in approximately 8% of cases; the risk rises dramatically with repeated episodes.

In people with penises and testes, untreated gonorrhea or chlamydia can cause epididymitis — painful inflammation of the epididymis (the coiled tube at the back of the testicle that stores sperm). Epididymitis can impair fertility and cause chronic discomfort. Reactive arthritis, an inflammatory condition affecting joints and occasionally eyes, is a rare but serious complication of both infections. Disseminated gonococcal infection — where gonorrhea spreads via the bloodstream — can cause skin lesions, joint pain, and, rarely, endocarditis or meningitis, though this is uncommon.

For pregnant people, untreated chlamydia and gonorrhea increase the risk of premature rupture of membranes, preterm delivery, and low birth weight. Maternal infection can also be transmitted to the newborn during delivery, causing conjunctivitis (eye infection) and, in the case of chlamydia, pneumonia. These complications are entirely preventable through routine antenatal screening and prompt treatment — underscoring why pregnancy is an important checkpoint for STI testing even in people who feel well.

Diagnosis: What Testing Involves

Nucleic acid amplification tests (NAATs) are the gold standard for diagnosing both chlamydia and gonorrhea. NAATs are highly sensitive and specific — they detect minute quantities of bacterial genetic material with very low rates of false positives or negatives. For genital infections, a first-void urine sample or a self-collected vaginal swab is sufficient and eliminates the need for a pelvic examination in most cases. Throat and rectal swabs require separate specimens because genital specimens do not reliably detect infection at other sites — a common oversight that leads to missed diagnoses in MSM and others who have oral or anal sex.

Results from NAAT testing are typically available within one to three days from a laboratory, though point-of-care rapid tests for gonorrhea are increasingly available at sexual health clinics and can provide results within 30–90 minutes. Rapid testing allows same-visit treatment, which reduces loss to follow-up and ensures the infection is treated before the person potentially exposes further partners. Gonorrhea cultures, while slower, are sometimes performed alongside NAATs to assess antibiotic sensitivity — increasingly important in the context of antimicrobial resistance.

Treatment: Antibiotics, Resistance, and What to Expect

Chlamydia is reliably treated with antibiotics. Doxycycline (100mg twice daily for seven days) is the current preferred regimen in most guidelines; azithromycin (a single 1g dose) is an alternative though it has shown lower efficacy for rectal chlamydia in some studies. Treatment is highly effective when completed. People should abstain from sex — including oral sex — for seven days after a single-dose treatment or until after completing a seven-day course, and until any partners have been treated.

Gonorrhea treatment is more complicated because of antimicrobial resistance. Neisseria gonorrhoeae has successively developed resistance to penicillin, tetracyclines, fluoroquinolones, and some cephalosporins. Current guidelines in many countries recommend injectable ceftriaxone as the first-line treatment. Some regions additionally prescribe oral azithromycin as a second agent to provide dual therapy, though azithromycin resistance is increasing. Multidrug-resistant gonorrhea — where available treatments fail — is a growing and serious concern that the WHO identifies as a global health priority. This evolving resistance landscape makes it essential to test after treatment (a 'test of cure' at two weeks) when treating gonorrhea at any site.

Prevention Beyond Condoms

Condoms, when used consistently and correctly, reduce chlamydia and gonorrhea transmission substantially — estimates range from 50–75% efficacy across studies, depending on consistency of use and sexual practices. Regular testing and prompt treatment — including partner notification and treatment — interrupt transmission chains and reduce reinfection rates. Doxycycline post-exposure prophylaxis (doxy-PEP), in which a single dose of doxycycline is taken within 72 hours of unprotected sex, has shown significant reductions in chlamydia and syphilis in clinical trials among MSM, and is now recommended in some national guidelines as an additional prevention tool for high-risk individuals.

Vaccination against gonorrhea is an active area of research — the meningococcal B vaccine (MenB/Bexsero) has shown modest cross-protection against gonorrhea in observational studies, likely because the bacteria share surface proteins. This finding is promising but does not yet support routine vaccination solely for gonorrhea prevention. Dedicated gonorrhea vaccine candidates are in development. Staying informed through sexual health providers about emerging prevention options is worthwhile for people at ongoing elevated risk.

Frequently Asked Questions

If I was treated for chlamydia or gonorrhea, can I get it again? Yes. Successful treatment clears the current infection but does not confer immunity. Reinfection is entirely possible and actually common — studies find that 10–30% of people diagnosed with chlamydia are reinfected within months, often because a partner was not treated or a new exposure occurred. This is why a follow-up test three months after treatment is recommended, and why partner notification and treatment are as important as treating the index case.

My partner has no symptoms — do they still need to be treated? Yes, absolutely. Asymptomatic infection is the norm, not the exception. A partner who feels fine is just as capable of harbouring and transmitting the infection. Treating symptomatic cases without tracing and treating partners results in rapid reinfection of the treated person. Partner notification — either done directly or through a clinic-based service — followed by treatment, is the standard of care for both infections.

Can chlamydia or gonorrhea be transmitted through oral sex? Yes, particularly gonorrhea, which infects the throat (pharyngeal gonorrhea) readily during oral sex. Pharyngeal gonorrhea is often asymptomatic, which means throat swabs are essential for anyone who performs oral sex and is at risk, not just genital swabs. Chlamydia can also infect the throat, though pharyngeal chlamydia is less common and less studied. Condoms and dental dams during oral sex reduce transmission risk at these sites.